January Podcast: Most Notable Stories Of 2014
This article was originally published in The Pink Sheet Daily
Executive Summary
Biosimilars, FDA's breakthrough designation, and oncology strategies were among topics that drew the greatest reader interest this past year. Our latest "Pinkcast" recaps some key stories, traces subsequent developments, and notes key actions to watch for in 2015.
You may also be interested in...
Sanofi Board Forces CEO Chris Viehbacher to Resign Amid Lantus Woes
Sanofi announced that Christopher Viehbacher has resigned as CEO after its board voted unanimously to remove him. The drama comes amid serious worries over the group’s cash cow medicine, Lantus.
FDA Changes Own Tweets To Match Industry Guidance
PhRMA says agency’s previous tweets on drug approvals set reasonable standards, and wants firms to be able to adopt format that FDA had used.
FDA Expecting 10 Biosimilar Applications Submitted By End Of FY 2015
The agency says it expects to receive three biosimilar marketing applications in fiscal year 2014 and another seven in FY 2015, as well as much more in program revenue.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: